Tuksadon Wutikhun

Layer-by-layer engineered nanocapsules of curcumin with improved cell activity.

Nanocarriers based on electrostatic Layer-by-layer (LbL) assembly of CaCO3 nanoparticles (CaCO3 NPs) was investigated. These inorganic nanoparticles was used as templates to construct nanocapsules made from films based on two oppositely charged polyelectrolytes, poly(diallyldimethylammonium chloride), and poly (sodium 4-styrene-sulfonate sodium salt), followed by core dissolution. The naked CaCO3 NPs, CaCO3 NPs coated with the polyelectrolytes and hollow nanocapsules were found with hexagonal shape with average sizes of 350-400 nm. A reversal of the surface charge between positive to negative zeta potential values was found, confirming the adsorption of polyelectrolytes. The loading efficiency and release of curcumin were controlled by the hydrophobic interactions between the drug and the polyelectrolyte matrix of the hollow nanocapsules. The quantity of curcumin released from hollow nanocapsules was found to increase under acidic environments, which is a desirable for anti-cancer drug delivery. The hollow nanocapsules were found to localize in the cytoplasm and nucleus compartment of Hela cancer cells after 24 h of incubation. Hollow nanocapsules were non-toxic to human fibroblast cells. Furthermore, curcumin loaded hollow nanocapsules exhibited higher in vitro cell inhibition against Hela cells than that of free curcumin, suggesting that polyelectrolyte based-hollow nanocapsules can be utilized as new carriers for drug delivery.

Surface modification of PLGA nanoparticles by carbopol to enhance mucoadhesion and cell internalization

Mucoadhesive poly (lactic-co-glycolic acid) (PLGA) nanoparticles having a modified shell-matrix derived from polyvinyl alcohol (PVA) and Carbopol (CP), a biodegradable polymer coating, to improve the adhesion and cell transfection properties were developed. The optimum formulations utilized a CP concentration in the range of 0.05-0.2%w/v, and were formed using modified emulsion-solvent evaporation technique. The resulting CP-PLGA nanoparticles were characterized in terms of their physical and chemical properties. The absorbed CP on the PLGA shell-matrix was found to affect the particle size and surface charge, with 0.05% CP giving rise to smooth spherical particles (0.05CP-PLGA) with the smallest size (285.90 nm), and strong negative surface charge (-25.70 mV). The introduction of CP results in an enhancement of the mucoadhesion between CP-PLGA nanoparticles and mucin particles. In vitro cell internalization studies highlighted the potential of 0.05CP-PLGA nanoparticles for transfection into SiHa cells, with uptake being time dependent. Additionally, cytotoxicity studies of CP-PLGA nanoparticles against SiHa cancer cells indicated that low concentrations of the nanoparticles were non-toxic to cells (cell viability >80%). From the various formulations studied, 0.05CP-PLGA nanoparticles proved to be the optimum model carrier having the required mucoadhesive profile and could be an alternative therapeutic efficacy carrier for targeted mucosal drug delivery systems with biodegradable polymer.

Phospholipid-chitosan hybrid nanoliposomes promoting cell entry for drug delivery against cervical cancer

This study emphasizes the development of a novel surface modified liposome as an anticancer drug nanocarrier. Quaternized N,O-oleoyl chitosan (QCS) was synthesized and incorporated into liposome vesicles, generating QCS-liposomes (Lip-QCS). The Lip-QCS liposomes were spherical in shape (average size diameter 171.5±0.8nm), with a narrow size distribution (PDI 0.1±0.0) and zeta potential of 11.7±0.7mV. In vitro mucoadhesive tests indicated that Lip-QCS possesses a mucoadhesive property. Moreover, the presence of QCS was able to induce the cationic charge on the surface of liposome. Cellular internalization of Lip-QCS was monitored over time, with the results revealing that the cell entry level of Lip-QCS was elevated at 24h. Following this, Lip-QCS were then employed to load cisplatin, a common platinum-containing anti-cancer drug, with a loading efficiency of 27.45±0.78% being obtained. The therapeutic potency of the loaded Lip-QCS was investigated using a 3D spheroid cervical cancer model (SiHa) which highlighted their cytotoxicity and apoptosis effect, and suitability as a controllable system for sustained drug release. This approach has the potential to assist in development of an effective drug delivery system against cervical cancer.

Efficiency of resveratrol-loaded sericin nanoparticles: Promising bionanocarriers for drug delivery

Sericin protein nanoparticles are a biocompatible, bio-viable class of nanocarriers gaining prominence in drug delivery system. This research aimed to investigate the suitability fabrication of silk protein (SP) nanoparticles for loading with resveratrol (RSV) via a solventless precipitation technique. The addition of 0.5% (w/v) pluronic surfactant proved optimal for SP nanoparticle fabrication, with obtained nanoparticles being spherical, mono-dispersed and having mean size of approximately 200-400 nm. All exhibited negative surface charges, the extent of which being dependent on the SP concentration, and were non-toxic to normal skin fibroblasts (CRL-2522). Loading of RSV, a promising which poorly soluble multi-targeted anti-oxidative and anti-inflammatory natural polyphenol, into SP nanoparticles proved feasible, with encapsulation levels of 71-75% for 0.6% and 1.0% (w/v) nanoparticle formulations, respectively. Resveratrol-loaded SP nanoparticles strongly inhibited growth of colorectal adenocarcinoma (Caco-2) cells although proved non-cytotoxic to skin fibroblasts, as indicated by cell viability assays. Cellular internalization of SP nanoparticles proved facile and dependent on incubation time; transfection of these carriers, in vitro results indicating sustained release of RSV (over 72 h), and drug solubility enhancements on encapsulation highlight their potential in therapeutic and pharmaceutical applications. Thus, SP nanoparticles is a promising approach to be potential bio-nanocarrier for drug delivery system.

Modified NLC-loaded coumarin for pharmaceutical applications: the improvement of physical stability and controlled release profile

Abstract Background: Coumarin-6 is a lipophilic dye and is often used as a model in delivery system. Objective: The aim of this study was to improve the nonstructured lipid carrier (NLC) system loading with lipophilic molecule, coumarin-6, and to investigate its characteristics in terms of physical stability and controlled release profile. Materials and methods: Initially, the selection of the coating polymer was observed. Then, the preparation of the conventional NLC-loaded coumarin-6 was compared to the modified NLC-loaded coumarin-6 via the probe sonication. The physical properties and stability were determined by Fourier transform infrared spectroscopy (FT-IR), differential scanning calorimetry (DSC) and X-ray diffraction (XRD) techniques. The release profile was established using fluorescent spectroscopic method. Results and discussion: The size and zeta potential measurement showed significant decrease in the size range of the modified NLC-loaded coumarin and the lower intensity of the surface charge compared to the NLC-loaded coumarin. The change of crystallinity observed from DSC and XRD techniques indicated the molecular dispersion of coumarin-6 in the lipid matrix of NLC. The FT-IR spectra were also proven that coumarin-6 was entrapped in the NLC molecule. The result showed comparable controlled release profile to the conventional preparation with no difference on the cytotoxicity level. Conclusions: The modified NLC delivery system, therefore, exhibited the acceptable potential as a nanocarrier.

Alterations of mineralized matrix by lead exposure in osteoblast (MC3T3-E1) culture

The present study investigated the effect of lead (Pb) on bone ultrastructure and chemistry using an in vitro bone model. MC3T3-E1 preosteoblasts were differentiated and treated with lead acetate at 0.4, 2, 10, and 50 μM. No abnormalities in either cell growth or bone nodule formation were observed with the treated dose of lead acetate. However, Pb treatments could significantly increase Pb accumulation in differentiated osteoblast cultures and upregulate expression of Divalent metal transporter 1 (Dmt1) in a dose dependent manner. Pb treatments also altered the expression of osteogenic genes, including secreted phosphoprotein 1, osteocalcin, type I collagen, and osteoprotegerin. Moreover, in mineralized osteoblast cultures, Pb was found to be mainly deposited as Pb salts and oxides, respectively. Ultrastructure analysis revealed Pb localizing with calcium and phosphorus in the mineralized matrix. In mineralizing osteoblast cells, Pb was found in the intracellular calcified vesicles which is one of the bone mineralization mechanisms. Pb was also present in mineral deposits with various shapes and sizes, such as small and large globular or needle-like mineral deposits representing early to mature stages of mineral deposits. Furthermore, Pb was found more in the globular deposits than the needle shaped mineral crystals. Taken together, our observations revealed how Pb incorporates into bone tissue, and showed a close association with bone apatite.